Program
irafamdastat
Also written as “BMS-986368”, “Irafamdastat” and “[14C]-BMS-986368”.
Its studies are mostly in Muscle Spasticity · Alzheimer Disease, led by Bristol-Myers Squibb.
Furthest: phase 2, since Jan 15, 20258 company-led studies, 4 open or runningNext primary completion: Dec 19, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 84 open or running | phase 2since Jan 15, 2025 | Sep 9, 2021 | Dec 19, 2026phase 1 · NCT07837115 |
- Named in Bristol-Myers Squibb’s own pipeline as
irafamdastat
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 9, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05099822 · 84 enrolled · Belgium
- Dec 6, 2023Phase 1 study in Healthy ParticipantsNCT06170723 · 32 enrolled · United States
- Jan 19, 2024Phase 1 study in Healthy VolunteersNCT06227975 · 8 enrolled · United States
- Apr 29, 2024Phase 1 study in Healthy ParticipantsNCT06411730 · 56 enrolled · United States
- Jan 15, 20252 phase 2 studiesNCT06782490, NCT06808984
- Jul 9, 2026Phase 1 study in Healthy VolunteersNCT07700329 · 16 planned
- Sep 16, 2026Phase 1 study in Healthy VolunteersNCT07837115 · 24 planned · United States
Ahead
- Dec 19, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07837115
- Feb 23, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07700329
- May 26, 2027Primary completion: phase 2 study in Muscle SpasticityNCT06782490
- Nov 26, 2027Primary completion: phase 2 study in Psychomotor AgitationNCT06808984
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07837115Healthy Volunteers · United States | 1 | Recruiting | Dec 19, 2026 | 24 |
| NCT07700329Healthy Volunteers | 1 | Not yet recruiting | Feb 23, 2027 | 16 |
| NCT06808984Psychomotor Agitation · United States, Argentina, Australia and more | 2 | Recruiting | Nov 26, 2027 | 120 |
| NCT06782490Muscle Spasticity · United States, Australia, Canada and more | 2 | Recruiting | May 26, 2027 | 200 |
| NCT06411730Healthy Participants · United States | 1 | Completed | Oct 28, 2024 | 56 |
| NCT06227975Healthy Volunteers · United States | 1 | Completed | Apr 3, 2024 | 8 |
| NCT06170723Healthy Participants · United States | 1 | Completed | May 25, 2024 | 32 |
| NCT05099822Healthy Volunteers · Belgium | 1 | Terminated | Jul 11, 2022 | 84 |
How it is read
Names in the registry
- “BMS-986368”, 5 entries
- “Irafamdastat”, 1 entry
- “[14C]-BMS-986368”, 1 entry
- “CC-97489”, 1 entry
Conditions, from the studies’ own filings
- Muscle Spasticity, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.